Have you made Baked Beet Salad?
Total Time: 5 hours and 50 min.
1. Remove stems and leaves from beets; wrap beets and onion separately in foil to make 2 packages.
2. Bake in 350F 180C oven for about 1 hour or until vegetables are fork-tender.
3. Remove vegetables from foil; let stand for 15-20 minutes or until cool enough to handle.
4. Loosen skins from vegetables; slice onion into strips and cube beets.
5. Vinaigrette: Meanwhile, in large bowl, whisk together oil, vinegar, mint, mustard, salt and pepper.
6. Toss vegetables with vinaigrette: let stand at room temperature for 1 hour or up to 4 hours.
This recipe contains potential food allergens and will effect people with Beet, Sulfites, Mustard, Hot Pepper, Vinegar, Onion allergies.


text:
KING TUPOU V OF TONGA LEAVES A LASTING LEGACY
Submitted by admin on Tue, 03/20/2012 - 00:00
Monarch responsible for reforms remembered fondly
WELLINGTON, New Zealand (Radio New Zealand International, March 19, 2012) – The King of Tonga, George Tupou V, has died in a Hong Kong hospital.
The official announcement of His Majesty's passing on was made early this morning at about 6am on Radio Tonga.
The official announcement was made by the Prime Minister, Lord Tu'ivakano, as per protocol.
It says His Majesty passed away at St. Mary's hospital of Hong Kong at 3pm local time on Sunday.
It says the untimely death of His Majesty "po'uli mo e loa ta'e'amanekina," "an unexpected black storm cloud" has covered the entire Kingdom.
His brother and heir-apparent to the Throne, Crown Prince Tupouto'a Lavaka was beside His Majesty when he passed away.
The announcement asks the nation to pray for comfort for the Royal Family and all the people of Tonga during this sad time.
Tupou V was sworn in as king in September 2006 following the death of his father king Taufa'ahau Tupou IV.
However his coronation was delayed until 2008 as the tiny kingdom reeled from the impact of riots in the capital Nuku'alofa.
[PIR editor's note: Dr. Feleti Sevele, who worked with the late king on democratic reform processes, called the king "one of the most brilliant minds I've ever come across." Dr. Sitiveni Halapua added that the king "oversaw fundamental political change in Tonga," notwithstanding the important transition towards more democratic government.]
A pro-democracy MP in Tonga says it is a dark moment for the Kingdom.
Akilisi Pohiva says the Prime Minister made a statement on local media this morning, announcing the King's death.
Mr. Pohiva says King George's legacy will be ushering in increased democracy in Tonga.
"I think everyone feels and sympathizes with the passing away of our king. We Tongans regard the action, or the moves made by His Majesty to increase the number of people's representatives from 9 to 17, as a historical event. And although political reform is not yet complete, his willingness to start is a very significant event."
The chair of the Tongan Advisory Council, Melino Maka, says King George will be remembered for accelerating democratic changes in the country.
Mr. Maka says, putting aside the King's reportedly lavish lifestyle, he has done great things for Tonga.
"For us and for those who have been have been calling for a more democratic Tonga, it is sad, because he masterminded all the changes that Tonga is currently having at the moment."
An Auckland based lawyer, Kahu Barron Afeaki, says people are in shock by the news.
"Tonga's reeling, both overseas, and in Tonga. It will take a while to absorb what's happened. In my view, King George V gave more than just a hastening of democracy, he actually gave a lot more freedom and gave a lot more power to the people."
[PIR editor's note: Meanwhile, at home and abroad, Tongan flags will fly at half-mast out of respect and mourning for King Tupou V. Tonga's Free Wesleyan Church has begun preparations for the king's funeral as officials travel to Hong Kong to discuss arrangements with the newly-crowned king.]
Ni-Vanuatu Film Stars Head To Hollywood For Academy Award Ceremony
GREENPEACE JOINS TANAPAG RESIDENTS IN FIGHT AGAINST PCB
U.S. Disaster Loans Available For Impacted FSM Businesses
Papua New Guinean Wins International World Of Children Award

redpajama_set_name: RedPajamaCommonCrawl


text:
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Published Wed, Apr 11 20183:15 PM EDT Updated Wed, Apr 11 20187:20 PM EDT
Tae Kim@firstadopter
Yuri Arcurs | Getty Images
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
Biotech shares soar on dealmaking, drug progress
Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.
"GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise."
The analyst didn't immediately respond to a request for comment.
The report suggested three potential solutions for biotech firms:
"Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually."
"Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe."
"Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets."
Biotech and Pharmaceuticals